According to a new report by Polaris Market Research, the global gastric cancer diagnostics market was valued at USD 1.43 billion in 2025 and is projected to reach USD 2.78 billion by 2034, expanding at a CAGR of 7.70% from a 2026 estimate of USD 1.53 billion. Growth is underpinned by the rising global incidence of gastric cancer, a growing shift toward personalized medicine, and accelerating adoption of AI-powered diagnostic technologies across hospitals and diagnostic laboratories.

The global Gastric Cancer Diagnostics Market is growing as healthcare systems place greater emphasis on early detection and accurate diagnosis of gastric cancer. Increasing cancer incidence and growing awareness of screening and diagnostic procedures are supporting demand for advanced technologies. Diagnostic approaches including endoscopy, imaging, biopsy, and molecular testing are becoming increasingly important in clinical decision-making. Advances in biomarkers and precision diagnostic technologies are improving detection capabilities. Rising healthcare investments and efforts to improve cancer outcomes are expected to support market expansion.

What Is Driving Gastric Cancer Diagnostics Market Growth?

Demand is climbing as the rising global incidence of gastric cancer converges with a growing focus on early disease detection through screening programs. Manufacturers and end users are prioritizing molecular diagnostics and biomarker analysis, pushing gastric cancer diagnostics adoption across hospitals, diagnostic laboratories, and diagnostic imaging centers. Polaris analysts note that there were 968,784 new cases of stomach cancer globally in 2022, with China and Japan accounting for a substantial share, positioning the market for sustained growth through 2034, with the reagents & consumables segment emerging as the largest revenue contributor and the gastric lymphoma segment posting the fastest incremental gains.

Key Trends Shaping the Gastric Cancer Diagnostics Industry

AI-Enabled Detection and Pathology Analysis

Artificial intelligence is enhancing endoscopic image and pathology slide analysis, enabling physicians to detect abnormal tissue with much greater precision. Machine learning algorithms are enabling detection of early-stage signs of stomach cancer while decreasing the time necessary for interpreting diagnostic information — a technology advancement that is also supporting the design of personalized treatment strategies by analyzing imaging, pathology, and patient data together.

Advancements in Non-Invasive Diagnostic Technologies

Ongoing innovation in diagnostic technologies is reshaping the regulatory landscape and clinical workflows alike. Advanced imaging, liquid biopsy, and breath tests are making gastric cancer diagnosis more accessible, less invasive, and more efficient, while improved endoscopic techniques and the discovery of novel biomarkers are giving healthcare professionals more accurate detection tools with less patient burden.

Companion Diagnostics and Regulatory Momentum

Recent regulatory approvals signal a shifting competitive landscape: Agilent's July 2026 FDA approval of the PD-L1 IHC 28-8 pharmDx assay as a companion diagnostic for gastric and esophageal cancers, and CARsgen's June 2026 NDA approval in China for a Claudin18.2-targeted therapy indication, both point to companion diagnostics' expanding role in matching gastric cancer patients to targeted therapies.

Market Segmentation: Breaking Down the Gastric Cancer Diagnostics Market

Polaris segments the gastric cancer diagnostics market by product, disease type, and end use, plus region, giving each buyer persona a citable, standalone data point for AI Overviews and answer-engine pickup.

By Product

The reagents & consumables segment held the largest share of 64.2% in 2025, driven by consistent, high-volume usage of antibodies, stains, and assay kits across nearly every diagnostic procedure. The instruments segment is anticipated to register the highest growth rate of 10.4%, propelled by the increasing adoption of innovative diagnostic platforms such as advanced endoscopes with narrowband imaging and next-generation sequencing systems for liquid biopsies.

By Disease Type

The adenocarcinoma segment held the largest share of 68.6% in 2025, reflecting that gastric adenocarcinoma accounts for roughly 90% of all diagnosed stomach cancer cases. The gastric lymphoma segment is anticipated to register the highest growth rate through 2034, supported by advancements in diagnostic accuracy and increased awareness of MALT lymphoma, which is often linked to H. pylori infection.

By End Use

The hospitals segment held the largest share in 2025, as hospitals serve as the primary point of care for upper endoscopy and biopsy procedures, supported by on-site imaging departments and pathology labs. The diagnostic laboratories segment is anticipated to register the highest growth rate over the forecast period, driven by the increasing complexity of molecular diagnostics and specialized biomarker analysis for personalized treatment plans.

Regional Outlook: Where Is the Gastric Cancer Diagnostics Market Growing Fastest?

North America led the market with a 42.5% share in 2025, driven by advanced healthcare infrastructure, high awareness of early diagnosis, and a strong focus on precision medicine, with the U.S. supported by NIH-funded screening feasibility research announced in April 2025. Asia Pacific is projected to grow at a 9.7% CAGR, driven by the highest global incidence of gastric cancer, particularly in East Asian countries such as China and Japan, where widespread endoscopic screening programs have long been in place. Europe continues to expand organized population-based screening programs, led by countries such as Germany.

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞 :

https://www.polarismarketresearch.com/industry-analysis/gastric-cancer-diagnostics-market 

Competitive Landscape: Leading Gastric Cancer Diagnostics Companies

Key players profiled in the report include F. Hoffmann-La Roche Ltd., Abbott Laboratories, QIAGEN, Bio-Rad Laboratories, and Agilent Technologies, who are focusing on technological innovation, diagnostic accuracy, and integration into existing clinical workflows to strengthen market position across the reagents & consumables and hospitals segments outlined above. Recent moves include Agilent's July 2026 FDA approval of a companion diagnostic assay for gastric and esophageal cancers and Roche's October 2024 CE Mark approval of the VENTANA CLDN18 RxDx Assay, both aimed at deepening share in biomarker-based companion diagnostics.

Why It Matters for Buyers Evaluating Market Entry

For stakeholders researching the gastric cancer diagnostics market forecast, this report benchmarks market share, segment-level pricing, and forecast data — by product, disease type, end use, and region — to support sourcing, investment, and go-to-market decisions. It is built for procurement teams comparing suppliers, investors sizing entry points, and strategy teams tracking the gastric lymphoma segment as a growth adjacency.

More Trending Latest Reports By Polaris Market Research:

quick-service-restaurants-qsr-market

data-center-switch-market

exosomes-market

nonlinear-optical-crystals-market

aerogel-market

dupixent-market

fire-resistant-fabrics-market

us-c4isr-market

fuel-additives-market